Novel Therapeutic Approach for Type 1 Diabetes: vTv Therapeutics is developing TTP399, an oral, liver-selective glucokinase activator, representing a novel mechanism of action with the potential to improve glycemic control in Type 1 Diabetes without increasing hypoglycemia risk.

Addressing High Unmet Medical Needs: Their lead product candidate, TTP399, targets Type 1 Diabetes, a chronic condition with significant patient burden and a lack of convenient oral treatment options beyond insulin.

Positive Clinical Proof-of-Concept Data: TTP399 has demonstrated promising results in Phase 2 clinical trials (STEADFAST study) for Type 1 Diabetes, providing a strong foundation for continued development and de-risking the asset.